In the latest trading session, 2.04 million EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) shares changed hands as the company’s beta touched 1.39. With the company’s most recent per share price at $8.32 changing hands around $0.7 or 9.19% at last look, the market valuation stands at $567.85M. EYPT’s current price is a discount, trading about -272.48% off its 52-week high of $30.99. The share price had its 52-week low at $6.90, which suggests the last value was 17.07% up since then. When we look at EyePoint Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.57 million shares, with the 3-month average coming to 833.27K.
Analysts gave the EyePoint Pharmaceuticals Inc (EYPT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.08. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended EYPT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. EyePoint Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.48.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Instantly EYPT is in green as seen in intraday trades today. With action 7.63%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 11.68%, with the 5-day performance at 7.63% in the green. However, in the 30-day time frame, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is 0.73% up. Looking at the short shares, we see there were 10.58 million shares sold at short interest cover period of 11.81 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 62.18% from its recent market value. According to analyst projections, EYPT’s forecast low is 22 with 22 as the target high. To hit the forecast high, the stock’s price needs a -164.42% plunge from its current level, while the stock would need to soar -164.42% for it to hit the projected low.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
Data shows that the EyePoint Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -3.26% over the past 6 months, a -17.03% in annual growth rate that is considerably lower than the industry average of 16.00%. Year-over-year growth is forecast to reach -7.63% down from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 11.02M. 5 analysts are of the opinion that EyePoint Pharmaceuticals Inc’s revenue for the current quarter will be 8.09M. The company’s revenue for the corresponding quarters a year ago was 14.03M and 11.68M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -21.42%. The estimates for the next quarter sales put growth at -30.77%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 29.57%. The 2025 estimates are for EyePoint Pharmaceuticals Inc earnings to decrease by -19.37%, but the outlook for the next 5-year period is at -15.76% per year.
EYPT Dividends
EyePoint Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.14% of EyePoint Pharmaceuticals Inc shares while 94.42% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.51%. There are 94.42% institutions holding the EyePoint Pharmaceuticals Inc stock share, with CORMORANT ASSET MANAGEMENT, LP the top institutional holder. As of 2024-06-30, the company held 15.7334% of the shares, roughly 8.32 million EYPT shares worth $72.43 million.
SUVRETTA CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 9.7818% or 5.18 million shares worth $45.03 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund. With 2.04 shares estimated at $16.61 million under it, the former controlled 2.99% of total outstanding shares. On the other hand, Federated Hermes Kaufmann Small Cap Fund held about 2.36% of the shares, roughly 1.61 shares worth around $13.13 million.
